Benchmarks

Benchmarks for the Measures

A variety of national organizations have developed bench marks with respect to some of the quality metrics collected by the Consortium. Below is more information regarding such benchmarks.

TABLE 1. Screening mammography measures and targets

Measure
Definition
Breast Cancer Surveillance Consortium Benchmarks*
ACR Benchmarks
Recall Rate
Proportion of screening mammograms interpreted as abnormal
10.6 %
< 10%
Lost to follow-up imaging
Proportion of abnormal (BI-RADS 0) screeners without follow-up imaging within 12 months
N/A
Ideal = 0%
Timeliness of follow-up imaging
Proportion of abnormal (BI-RADS 0) screeners with follow-up imaging within 30 days N/A 
Ideal = 100%
PPV1
Cancer detection rate among abnormal screens
4.4 %
5-10 %
Screen-Detection Rate
Cancers detected following an abnormal screen, per 1000 screens
4.7
2-10
Proportion Minimal
DCIS or invasive cancer ≤ 1 cm
52.6
> 30 %
Proportion Early Stage
Stage 0 or I cancer
74.8
> 50 % 

 

TABLE 2. Treatment measures and targets with respect to invasive breast cancer

Measure
Definition Ideal
State of IL (Commission on Cancer) 2006
In-situ
Proportion of Stage 0 cancers
N/A
N/A
Late Stage
Proportion of Stage 3 or 4 cancers
N/A
N/A
Radiation after BCS
Proportion of invasive cancers that were treated with radiation therapy following breast conserving surgery
100 %
90.5 %
Hormone therapy if receptor positive
Proportion of invasive cancers that were treated with hormone therapy if ER/PR +
100 %
78.6 %
Herceptin if Her2/neu positive
Proportion of invasive cancers that were treated with herceptin if HER2 +
--
N/A
 Timely Treatment
Proportion of cancers treated within 30 days of diagnosis
100%
N/A
I Need A Mammogram I Have Breast Cancer Community Services Get Involved Calendar Of Events